Expression of leptin, leptin receptor, adiponectin, and adiponectin receptor in ductal carcinoma in situ and invasive breast cancer. 2011

Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
Department of Surgery, Catholic University of Daegu School of Medicine, Daegu, Korea.

OBJECTIVE Adipocytokines, such as leptin, resistin, and adiponectin, are associated with obesity and breast cancer. Several studies have indicated that adipocytokines may influence tumor growth or differentiation. The aims of this study were to determine the expression of leptin, leptin receptor (ObR), adiponectin and adiponectin receptor (AdipoR) in human breast cancer, to evaluate their prognostic significance in the breast cancer. METHODS Specimens from 198 patients with primary breast cancer were enrolled, and representative paraffin tumor blocks were selected for constructing tissue microarrarys (TMA). Immunohistochemical staining for leptin, ObR, adiponectin, and AdipoR was performed using TMA, and the clinicopathologic characteristics were evaluated from the patient's medical records. RESULTS Stage 0 breast cancer accounted for 41 cases, and 157 cases were invasive cancer. Positive rates of leptin and ObR expression in the ductal carcinoma in situ (DCIS) group were significantly higher than those of the invasive cancer group (97.4% vs. 34.0%, p<0.001; 74.4% vs. 29.8%, p<0.001). However, positive rates of adiponectin and AdipoR expression in the invasive cancer group were significantly higher than those in the DCIS group (53.7% vs. 33.3%, p=0.024; 59.9% vs. 26.3%, p<0.001). High leptin expression was significantly associated with high Ki-67 expression (p=0.016). High adiponectin expression was significantly correlated with smaller tumor size (p=0.001). CONCLUSIONS We suggest that losses of leptin and ObR expression could be associated with invasive cancer, whereas high adiponectin and AdipoR expression may be associated with breast cancer invasiveness.

UI MeSH Term Description Entries

Related Publications

Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
July 2019, Cancers,
Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
May 2019, The American journal of pathology,
Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
October 2004, European journal of cancer (Oxford, England : 1990),
Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
April 2015, Oncotarget,
Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
June 1999, Oncogene,
Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
February 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
September 2005, International journal of cancer,
Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
May 1993, Journal of the National Cancer Institute,
Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
January 2020, The Journal of international medical research,
Young-Ju Jeong, and Jin-Gu Bong, and Sung-Hwan Park, and Jung-Hye Choi, and Hoon-Kyu Oh
October 2022, Asian journal of surgery,
Copied contents to your clipboard!